



An introduction to the new regulations on medical devices and new provisions related to use of hazardous substances

**Workshop | Can the Medical Devices Regulation be an engine for substitution?
Brussels, 06 November 2017**

Salvatore Scalzo

Unit D4 - Health Technology and Cosmetics
DG Internal Market, Industry, Entrepreneurship and SMEs
European Commission

Revision of the EU Medical Devices Legislation Background



Directive 90/385/EEC on active implantable medical devices
Directive 93/42/EEC on medical devices

Regulation 2017/745 on medical devices (MDR)



Directive 98/79/EC on *in vitro* diagnostic medical devices (IVDs)

Regulation 2017/746 on *in vitro* diagnostic medical devices (IVDR)



Main features of the new Regulations on medical devices (art 114-168 TFEU)

- ✓ Inclusion of **certain aesthetic devices** within the **scope**.
- ✓ EU minimum requirements related to **reprocessing of single-use devices**.
- ✓ **Stricter pre-market control** of high-risk devices with the involvement of a pool of experts at EU level.
- ✓ Reinforcement of the rules on **clinical evaluation** (and performance evaluation) and **clinical investigation** (and performance studies).
- ✓ **New classification system for IVDs** based on international guidance (80% of IVDs to be assessed by a Notified Body).
- ✓ **Reinforced designation and oversight** processes of **notified bodies**.
- ✓ Clarification of the role and responsibilities of **economic operators**.
- ✓ **Establishment of a comprehensive EU database on medical devices (EUDAMED)** with large part of information to be made publicly available.
- ✓ Introduction of a **UDI system**.
- ✓ Stricter requirements related to the **use of hazardous substances**.

Transitional period

25 May 2017

26 May 2020

26 May 2022



**Entry into
force of
Regulations**



**Full
application
of MDR at 3
years**



**Full
application of
IVDR at 5
years**

Key derogations

- 26 November 2017: Requirements on Notified Bodies; designation of Competent Authorities; establishment of MDCG
- 26 May 2018: Cooperation among Competent Authorities
- 26 November 2020: Designation of reference laboratories
- 26 November 2021/2023: Registration of devices
- 26 May 2021/2023/2025 (MD) - 26 May 2023/2025/2027 (IVD): Placement of UDI carrier
- 27 May 2024: Maximum period of validity of certificates issued under current Directives
- 27 May 2025: Making available of devices placed on the market pursuant to current Directives
- 26 May 2027: Coordinated procedure for clinical investigations

Regulation of hazardous substances in medical devices according to the new medical device Regulation 745/2017 (1/2)

● Conformity assessment of devices

- ✓ Manufacturers of medical devices required to provide adequate justification to the Notified Body with regard to the presence of CMR 1A and 1B and/or endocrine disruptors that are (cumulative)
 - ✓ contained in certain medical devices listed in the relevant provisions
 - ✓ above a certain concentration (0.1% weight by weight (w/w))
- ✓ Justification to be based also on scientific opinions from relevant Scientific Committees (when available)
 - ✓ Commission is required to provide the relevant Scientific Committee (SCHEER) with a mandate to prepare guidelines on the presence of phthalates in devices – guidelines to be adopted by the application date
 - ✓ Commission, whenever appropriate, should mandate the SCHEER to produce guidelines for substances other than phthalates
 - ✓ Those guidelines shall cover at least a benefit-risk assessment of the presence of substances. The benefit-risk assessment shall take into account i.a. any available alternative substances and alternative materials, designs or medical treatments

Regulation of hazardous substances in medical devices according to the new medical device Regulation 745/2017 (2/2)

● Transparency

- ✓ Presence of hazardous substances (subject to justification) to be indicated on the label of the device (in accordance with provisions laid down in Annex I 10.4.5)
- ✓ Information labelled in accordance with Annex I 10.4.5 is one of the mandatory UDI data elements to be provided by the manufacturer to the UDI database
 - ✓ UDI data elements are accessible to the public
 - ✓ Future EU medical device nomenclature to enhance database search functions

Implementation: priorities

- **Notified Bodies**
 - ✓ Implementing Act on codes (by 26 November 2017)
 - ✓ Other regulatory and logistical matters related to designation procedures
- **Mandate to SCHEER to produce guidelines on phthalates (completed)**
- **Governance**
 - ✓ Setting up of MDCG (and subgroups)
 - ✓ Establishment of expert panels, expert laboratories and reference laboratories
- **Design and establishment of EUDAMED**
- **Establishment of the UDI system**
- **Common specifications on Annex XVI products**
- **Common specifications on reprocessing**
- **Clarification of certain transitional provisions (cooperation with CAMD)**

Implementation: past meetings and next steps

● Past meetings

- ✓ Joint COM/CAMD workshop with stakeholders on 9 March 2017 and 18 October 2017 – preparation of a roadmap containing list of priorities for the implementation period
- ✓ EUDAMED: 4 meetings of the Steering Committee and 12 meetings of *ad hoc* Working Groups related to the 1st set of modules: Registration, UDI & Devices, NBs & Certificates and Data Exchange (13 meetings scheduled until April 2018)
- ✓ Draft Implementing Acts: 4 meetings with Member States on: 27-28 October 2016, 13-14 December 2016, 19 May 2017 and 5 October 2017

● Next steps (in Autumn)

- ✓ Publication of CAMD/COM roadmap – next few weeks
- ✓ Adoption Implementing Act on Notified Bodies codes: by 26 November 2017
- ✓ Notified Bodies applications for designation: as from 27 November
- ✓ Setting-up and first meeting of the MDCG: 28 November 2017
- ✓ Launch of the procedure for a corrigendum to the two Regulations: December 2017



***Thank you
for your attention***